Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.


BACKGROUND The development of vaccines against pandemic influenza viruses for use in children is a public health priority. METHODS In this phase II, randomized, open study, the immunogenicity and reactogenicity of H5N1 A/Vietnam/1194/2004 (NIBRG-14) (clade 1) prepandemic influenza vaccine were assessed in children aged 3 to 5 and 6 to 9 years. Children… (More)
DOI: 10.1097/INF.0b013e3181daf921


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.